Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists represent highly efficacious treatment options for type 2 diabetes. Liraglutide was amongst the first authorised for use in 2010, but once-weekly semaglutide represents the most efficacious GLP-1 analogue currently available for type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Berry, Sasha, Malkin, Samuel J. P., Hunt, Barnaby, Sharma, Abheet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203087/
https://www.ncbi.nlm.nih.gov/pubmed/37120480
http://dx.doi.org/10.1007/s13300-023-01408-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203087/
https://www.ncbi.nlm.nih.gov/pubmed/37120480
http://dx.doi.org/10.1007/s13300-023-01408-2

Ejemplares similares